The Pharma Letter's pipeline review 2019

Pipelines are the future of pharma, providing an indication of which patients, companies and shareholders will benefit from the next generation of cures and treatments.

With good reason, companies constantly fret about the strength of their candidates in development, comparing them to other drugmakers, throwing billions at new additions and pruning where appropriate to prevent R&D costs from spiralling even higher.

So where do things stand currently? The Pharma Letter has taken a look at the top 10 pharma companies—judged on 2017 revenues—to see how their pipelines are looking at the start of 2019, and which drugs are likely to start turning promise into profits.